Madrigal Pharmaceuticals, Inc. (MDGL)
NASDAQ: MDGL · Real-Time Price · USD
535.27
+19.93 (3.87%)
Aug 11, 2026, 4:00 PM EDT - Market closed
Madrigal Pharmaceuticals Stock Forecast
Stock Price Forecast
According to 17 analysts polled by S&P Global, Madrigal Pharmaceuticals stock has a consensus rating of "Strong Buy" and an average price target of $678.06. The average 1-year stock price forecast is 26.68% higher than the current stock price, while the lowest is $543 (+1.44%) and the highest is $962 (+79.72%).
Price Target: $678.06 (+26.68%)
Analyst Consensus: Strong Buy
Price Target
ChartAnalyst Ratings
The average analyst rating for Madrigal Pharmaceuticals stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Feb '26 | Mar '26 | Apr '26 | May '26 | Jun '26 | Jul '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 11 | 11 | 11 | 11 | 11 | 12 |
| Buy | 3 | 3 | 3 | 3 | 3 | 3 |
| Hold | 2 | 2 | 2 | 2 | 2 | 2 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 16 | 16 | 16 | 16 | 16 | 17 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Canaccord Genuity | Canaccord Genuity | Buy Reiterates $612 | Buy | Reiterates | $612 | +14.33% | Aug 12, 2026 |
| Wolfe Research | Wolfe Research | Buy Upgrades $605 | Buy | Upgrades | $605 | +13.03% | Aug 4, 2026 |
| Barclays | Barclays | Buy Maintains $964 → $962 | Buy | Maintains | $964 → $962 | +79.72% | Aug 3, 2026 |
Unknown Analyst B. Riley Securities No rating | B. Riley Securities | Buy Initiates $670 | Buy | Initiates | $670 | +25.17% | Jul 31, 2026 |
| Truist Financial | Truist Financial | Buy Reiterates $709 | Buy | Reiterates | $709 | +32.46% | Jul 31, 2026 |
Financial Forecast
Revenue This Year
1.53B
from 958.40M
Increased by 59.25%
Revenue Next Year
2.14B
from 1.53B
Increased by 40.53%
EPS This Year
-6.49
from -12.73
EPS Next Year
9.63
from -6.49
EPS and Forward PE are based on non-GAAP adjusted numbers.